Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Forsythiaside (specifically Forsythiaside A) is a phenylethanoid glycoside primarily isolated from the fruit of *Forsythia suspensa*, a traditional Chinese medicinal herb. Developed as a pharmaceutical candidate by Guangdong Lane Pharmaceutical Research Institute, it is being investigated for its potent broad-spectrum antiviral and anti-inflammatory properties in treating respiratory viral infections such as the common cold and influenza. The compound exhibits a dual mechanism of action: it inhibits viral replication by targeting neuraminidase activity and mitigates the inflammatory response by suppressing the NF-κB signaling pathway. This suppression leads to a significant reduction in the production of pro-inflammatory cytokines, including TNF-α and IL-6, which helps prevent the severe lung injury often associated with viral infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on forsythiaside.